The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Check out the companies making headlines after the bell:
Sprint stock dipped as much as 1.8 percent in after-hours trading after the Federal Communications Commission released a letter pausing the transaction clock for the proposed merger of Sprint and T-Mobile.
"Additional time is necessary to allow for thorough staff and third-party review of newly-submitted and anticipated modeling," the FCC said in the letter.
T-Mobile shares edged slightly higher in late trading.
Gilead shares rose over 2 percent in the extended session after its arthritis drug achieved its goals in a new study. The drug, filgotinib, is being developed along with Belgium-based Galapagos RV to tread rheumatoid arthritis and Crohn's disease.
Farmer Bros. stock fell about 2 percent in after-hours trading following the release of its fourth-quarter earnings report. The coffee company reported $149.5 million in revenue, less than the $152.6 million analysts expected, according to a Thomson Reuters consensus estimate.